Expanesthetics Featured in Anesthesiology News
A feature this month in Anesthesiology News spotlights Expanesthetics' work to discover the next generation of inhaled anesthetic compounds. The last new inhaled anesthetic in clinical use was discovered before we landed on the moon, and with mounting evidence linking intraoperative hypotension to real patient harm, the need for something new has never been clearer. This coverage follows Expanesthetics' recent publication in Anesthesia & Analgesia, and reflects the significance of what this community is building together.
"Being recognized in Anesthesiology News is a testament to the work this community continues to make possible. It's time for something new."
Dr. Shane Austin, Chief Executive Officer
Recent Updates
Expanesthetics Research Published in Anesthesia & Analgesia
Our first peer-reviewed publication describes BTTE, a novel inhaled anesthetic compound, including its physical properties, receptor activity, and physiologic effects in preclinical testing.
Read moreStudy Finds Post-Induction Hypotension Common in Older Patients Receiving Propofol
Coverage in Anesthesiology News reports that most patients age 65 and older experienced significant blood pressure reductions after induction with propofol, even at low doses. The findings highlight the ongoing hypotension challenge associated with currently used anesthetic agents.
Read moreDoctors Call for Balance Between Environmental Goals and Patient Needs
Several recent publications revisit how the environmental impact of inhaled anesthetics is measured and regulated. Authors note that commonly used carbon-equivalent comparisons may not fully reflect how short-lived anesthetic gases behave in the atmosphere, and emphasize balancing sustainability goals with clinical decision-making.
Read more